Endothelial Dysfunction in Psoriasis: An Updated Review
Front Med (Lausanne). 2022 Jun 10;9:864185. doi: 10.3389/fmed.2022.864185. eCollection 2022.ABSTRACTAlthough psoriasis is predominantly a chronic inflammatory skin disorder, epidemiological data provide a solid link between psoriasis, especially in its more severe forms, and increased risk for cardiovascular morbidity and mortality. Apart from the increased prevalence of traditional cardiovascular risk factors, chronic inflammation appears to act synergistically with the underlying process of endothelial dysfunction toward the development of accelerated atherosclerosis, subclinical vascular injury and subsequently, clinica...
Source: Atherosclerosis - June 27, 2022 Category: Cardiology Authors: Panagiota Anyfanti Anastasia Margouta Kyriakos Goulas Maria Gavriilaki Elizabeth Lazaridou Aikaterini Patsatsi Eugenia Gkaliagkousi Source Type: research

A High Programmed Cell Death Protein 1 Hormone Receptor Score on Skin Biopsy is Associated with S ézary Syndrome Diagnosis: A Study of 91 Patients with Erythroderma
This study reports the importance of programmed cell death protein 1 expression for the differential diagnosis of Sézary syndrome and other aetiologies, including erythrodermic mycosis fungoides.PMID:35758515 | DOI:10.2340/actadv.v102.1062 (Source: Acta Dermato-Venereologica)
Source: Acta Dermato-Venereologica - June 27, 2022 Category: Dermatology Authors: Camille Luherne Sarah Menguy Thomas Ferte Marie Beylot-Barry Julien Seneschal Brigitte Milpied Jean-Philippe Vial Audrey Gros Samuel Amintas B éatrice Vergier Anne Pham-Ledard Source Type: research

A High Programmed Cell Death Protein 1 Hormone Receptor Score on Skin Biopsy is Associated with S ézary Syndrome Diagnosis: A Study of 91 Patients with Erythroderma
This study reports the importance of programmed cell death protein 1 expression for the differential diagnosis of Sézary syndrome and other aetiologies, including erythrodermic mycosis fungoides.PMID:35758515 | DOI:10.2340/actadv.v102.1062 (Source: Acta Derm Venereol A...)
Source: Acta Derm Venereol A... - June 27, 2022 Category: Dermatology Authors: Camille Luherne Sarah Menguy Thomas Ferte Marie Beylot-Barry Julien Seneschal Brigitte Milpied Jean-Philippe Vial Audrey Gros Samuel Amintas B éatrice Vergier Anne Pham-Ledard Source Type: research

Place in therapy of anti-IL-17 and 23 in psoriasis according to the severity of comorbidities: a focus on cardiovascular disease and metabolic syndrome
. (Source: Expert Opinion on Biological Therapy)
Source: Expert Opinion on Biological Therapy - June 27, 2022 Category: Drugs & Pharmacology Authors: Emanuele Trovato Pietro Rubegni Francesca Prignano Source Type: research

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021
Nature Reviews Rheumatology, Published online: 27 June 2022; doi:10.1038/s41584-022-00798-0This Evidence-Based Guideline presents the latest treatment recommendations for medication selection in psoriatic arthritis (PsA), covering the six clinical domains of PsA, related conditions and associated comorbidities, and reflecting important advances in the field since the previous update. (Source: Nature Reviews Rheumatology)
Source: Nature Reviews Rheumatology - June 27, 2022 Category: Rheumatology Authors: Laura C. Coates Enrique R. Soriano Nadia Corp Heidi Bertheussen Kristina Callis Duffin Cristiano B. Campanholo Jeffrey Chau Lihi Eder Daniel G. Fern ández-Ávila Oliver FitzGerald Amit Garg Dafna D. Gladman Niti Goel Philip S. Helliwell M. Elaine Husni D Source Type: research

EE291 Psoriasis-Related Work Productivity Improvement from a Phase 4 Real-World Study Interim Analysis of Tildrakizumab in Patients with Moderate to Severe Psoriasis
We report improvement in work productivity and reduced activity impairment from the Week 28 interim analysis of a real-world study of patients with psoriasis treated with tildrakizumab. (Source: Value in Health)
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: N Bhatia, J Heim, P Beute, M Torres, B Schenkel, SJ Rozzo, JG Vasquez Source Type: research

EE382 Healthcare Utilization, Employment and Sickness Absence Among Patients with Psoriasis and Psoriatic Arthritis in Sweden: Descriptive Analysis from a Nationwide Register-Based Study
Evaluate the annual inpatient admission, outpatient visit, employment status and sickness absence among patients with PsO and PsA in Sweden. (Source: Value in Health)
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: Q Cai, RE Teneralli, S Peterson, I Rahman, C Contre, L Di Scala Source Type: research

EPH46 Change in Persistence between Biologic and Biosimilar of Infliximab in the US
Infliximab is a biologic drug administered in medical setting and has biosimilars like Infliximab-dyyb and Infliximab-abda are used in the US for the treatment of multiple diseases like rheumatoid arthritis, plaque psoriasis, ulcerative colitis, and crohn ’s disease. Our study aim is to identify and observe the change in persistence of infliximab and its two biosimilars for above mentioned diseases. (Source: Value in Health)
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: S Bhalani, N Mishra, A Gaur, I Kukreja, A Roy, A Chopra, A Gupta, L Brooks, M Sulzicki, V Verma, S Pandey, S Field, B Krebs Source Type: research

EPH142 Epidemiological Disease Burden and Cost of Illness of Psoriasis in the US
Psoriasis is a very common disease that affects almost 2% of the world ’s population and 7.5 million of the U.S. population. The cost of illness is an important metric to study for psoriasis because it can explain the economic burden of the disease. Aim of this study to determine and comprehend the disease burden of psoriasis, as well as the cost of psoriasis illness in the United States. (Source: Value in Health)
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: A Gupta, S Bhalani, A Chopra, F Jabin, A Gaur, I Kukreja, A Roy, L Brooks, M Sulzicki, V Verma, S Pandey Source Type: research

MSR55 Detecting Generalized Pustular Psoriasis Exacerbations in Unstructured Clinical Data Using Deep Neural Networks
Our objective was to identify generalized pustular psoriasis (GPP) patients experiencing exacerbations by analyzing the unstructured clinical patient data with machine learning (ML) methodologies. (Source: Value in Health)
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: V Kumar, L Rasouliyan, AG Althoff, S Long, C Zema, MB Rao Source Type: research

PCR96 Differences in Patient Reported Outcomes between Males and Females in an International Psoriasis Population
Assess potential differences in patient reported outcomes between males and females living with psoriasis. (Source: Value in Health)
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: M Molaei, F Yang, RF Cheng, W MacDonald, J Lucas, RE Teneralli Source Type: research

RWD3 Real-World Use of Biologics and Prescription Topical Medications in a Pediatric Psoriasis Population
A third of psoriasis (PsO) cases report onset during childhood, but few treatments are FDA-approved specifically for use in pediatric patients. The purpose of this analysis was to describe prescription topical and biologic treatment and percent body surface area (%BSA) in a real-world pediatric PsO population. (Source: Value in Health)
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: A Swenson, P Kumparatana, H Friedler, K Starzyk, J Paulus Source Type: research

RWD99 Initial Treatment Patterns for Newly Diagnosed, Commercially Insured Patients with Psoriasis
This study examined utilization rates and time-to-treatment initiation of first-line therapy among newly diagnosed, commercially insured patients. (Source: Value in Health)
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: L Panattoni, J Hernandez, Y Liu, N Sacks, R Higham, B Stephenson, AW Armstrong Source Type: research

RWD142 Clinical Characteristics of Chinese Patients with Psoriasis Receiving Interleukin-17A Inhibitors: A Single-Center Retrospective Analysis
To describe the disease characteristics in Chinese adult patients with psoriasis receiving interleukin-17A (IL-17A) inhibitors in a tertiary care clinic in Changsha, China. (Source: Value in Health)
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: K Hu, Q Wang, J Yang, M Tan, B Zhang, G Dou, Y Chen, W Chen, W Zhu, Y Kuang Source Type: research

One-Year Safety and Efficacy of Tapinarof Cream for the Treatment of Plaque Psoriasis: Results from the PSOARING 3 Trial
•Tapinarof cream 1% once daily was safe, well tolerated, and durably efficacious in patients with mild to severe psoriasis for up to 1 year, with 40.9% complete disease clearance rate, ∼4-month remittive effect, and no tachyphylaxis. •Tapinarof may represent a novel nonsteroidal topical therap y that addresses limitations of current therapies (Source: Journal of the American Academy of Dermatology)
Source: Journal of the American Academy of Dermatology - June 26, 2022 Category: Dermatology Authors: Bruce Strober, Linda Stein Gold, Robert Bissonnette, April W. Armstrong, Leon Kircik, Stephen K. Tyring, Stephen C. Piscitelli, Philip M. Brown, David S. Rubenstein, Anna M. Tallman, Mark G. Lebwohl Source Type: research